Merck's remigromig meets goal but data cloud outlook

· Health · United States

Merck reported that its ophthalmology candidate remigromig met the primary endpoint in a pivotal study in diabetic macular edema, but the full results raised questions about the drug's commercial prospects. The company had said last month that remigromig was non-inferior to an existing treatment. The candidate is positioned as a competitor to Lucentis in a market where rival eye drugs are already competing. Analysts are weighing whether the data are strong enough to support adoption against entrenched therapies.

Why it matters：A pivotal readout in a crowded eye-disease market shapes how payers, physicians and competitors view the next entrant in retinal therapies.

Key points

  • Remigromig met the primary endpoint in a pivotal diabetic macular edema study.
  • Merck said last month the drug was non-inferior to an existing treatment.
  • The full results raised questions about its commercial prospects.

Sources (original reporting)

More stories from this day